Lisa Walz

Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial

Cassandra Aldrich, Isabel Leroux‐Roels, Katell Bidet Huang et al. · Vaccine · 2021 · 201 citations · Full text

Pharmacy, Molecular Pharmaceutics, Pharmaceutics +17

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri et al. · The Lancet Infectious Diseases · 2021 · 175 citations · Full text

Veterinary Medicine, Infectious Diseases, Molecular Virology +16

Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles

Velislava Petrova, Bevan Sawatsky, Alvin X. Han et al. · Science Immunology · 2019 · 136 citations · Full text

Life Sciences, Genetics, Immunology +17

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2

Peter G. Kremsner, Philipp Mann, Arne Kroidl et al. · Wiener klinische Wochenschrift · 2021 · 132 citations · Full text

Veterinary Medicine, Immunology, Molecular Pharmaceutics +17

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

Peter G. Kremsner, Philipp Mann, Jacobus J. Bosch et al. · medRxiv · 2020 · 103 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17